{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:30Z","timestamp":1793212110865,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008870","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,7,3]],"date-time":"2016-07-03T00:00:00Z","timestamp":1467504000000}}],"reference-count":135,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008870.pub2","type":"journal-article","created":{"date-parts":[[2016,7,3]],"date-time":"2016-07-03T01:59:15Z","timestamp":1467511155000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Aminosalicylates for induction of remission or response in Crohn's disease"],"prefix":"10.1002","volume":"2016","author":[{"given":"Wee-Chian","family":"Lim","sequence":"first","affiliation":[{"name":"Tan Tock Seng Hospital; Department of Gastroenterology and Hepatology; 11 Jalan Tan Tock Seng Singapore Singapore S 308433"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Schulich School of Medicine & Dentistry; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"},{"name":"University of Western Ontario; Department of Medicine; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine; 676 N St Clair Suite 1400 Chicago IL USA 60611"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,3]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0002|cit2","unstructured":"Hoechst Marion Roussel Inc Clinical study report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's III)"},{"issue":"10","key":"10.1002\/14651858.CD008870.pub2-BIB0003|cit3","first-page":"581","article-title":"Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group","volume":"33","author":"Gross","year":"1995","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000200228","article-title":"Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease","volume":"45","author":"Mahida","year":"1990","journal-title":"Digestion"},{"issue":"10","key":"10.1002\/14651858.CD008870.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-2008-1068828","article-title":"Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid","volume":"110","author":"Maier","year":"1985","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/1990\/156847","article-title":"Clinical efficacy of oral mesalamine in Crohn's disease","volume":"4","author":"Maier","year":"1990","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD008870.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1155\/1990\/659079","article-title":"Oral 5-ASA versus prednisolone in short term treatment of Crohn's disease: A multicentre controlled trial","volume":"4","author":"Martin","year":"1990","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0016-5085(99)70172-1","article-title":"Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial","volume":"116","author":"Prantera","year":"1999","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD008870.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/00365528708991929","article-title":"5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa","volume":"22","author":"Rasmussen","year":"1987","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-114-6-445","article-title":"Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial","volume":"114","author":"Rijk","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000199279","article-title":"Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease","volume":"33","author":"Saverymuttu","year":"1986","journal-title":"Digestion"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD008870.pub2-BIB0013|cit13","first-page":"34","article-title":"5-Aminosalicylic acid versus methylprednisolone in the therapy of acute Crohn's disease - results of a double-blind multicentric clinical study","volume":"68","author":"Jenss","year":"1990","journal-title":"Klinische Wochenschrift"},{"issue":"7","key":"10.1002\/14651858.CD008870.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1155\/1990\/260563","article-title":"Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease","volume":"4","author":"Scholmerich","year":"1990","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/BF02064179","article-title":"Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease","volume":"40","author":"Singleton","year":"1995","journal-title":"Digestive Diseases and Sciences"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0017|cit17","unstructured":"Nordic Research Inc Clinical research report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's II)"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/0016-5085(94)90210-0","article-title":"Second trial of mesalamine therapy in the treatment of active Crohn's disease","volume":"107","author":"Singleton","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0020|cit19","first-page":"38","article-title":"Results of treatment with sulfasalazine in the American Multicenter Study on the treatment of Crohn disease (National Cooperative Crohn's Disease Study)","volume":"19","author":"Singleton","year":"1981 Jun","journal-title":"Zeitschrift fur Gastroenterologie - Verhandlungsband"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD008870.pub2-BIB0019|cit20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0016-5085(79)90386-X","article-title":"National Cooperative Crohn's Disease Study: adverse reactions to study drugs","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD008870.pub2-BIB0021|cit21","first-page":"A972","article-title":"National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo","volume":"18","author":"Summers","year":"1977","journal-title":"Gut"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD008870.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1572-0241.2002.05544.x","article-title":"Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life","volume":"97","author":"Thomsen","year":"2002 Mar","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology"},{"issue":"5 supplement 1","key":"10.1002\/14651858.CD008870.pub2-BIB0027|cit27","first-page":"A65","article-title":"Both budesonide (9mg) as well as high-dose eudragit-l-coated mesalamine(4.5g) lead to high remission rates in moderately active Crohn's disease patients: a double-blind, double-dummy, randomized, multicenter study","volume":"136","author":"Tromm","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.22.5.404","article-title":"Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study","volume":"22","author":"Hees","year":"1981","journal-title":"Gut"},{"issue":"SUPPL.","key":"10.1002\/14651858.CD008870.pub2-BIB0029|cit29","first-page":"E38.5","article-title":"Effect of sulphasalazine in patients with Crohn's disease. a controlled double-blind trial","volume":"27","author":"Hees","year":"1980","journal-title":"Hepato-Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0030|cit30","first-page":"157","article-title":"Effect of sulphasalazine in patients with active Crohn's disease. a controlled double-blind trial","volume":"24","author":"van","year":"1981","journal-title":"Netherlands Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00054725-199512000-00001","article-title":"A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease","volume":"1","author":"Wright","year":"1995","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02774676","article-title":"Salazopyrin in the management of Crohn's disease. The Japanese Research Committee for Crohn's disease","volume":"20","year":"1985","journal-title":"Gastroenterologia Japonica"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.1990.tb00449.x","article-title":"Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group","volume":"4","year":"1990","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0035|cit34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/00365521.1974.12096873","article-title":"The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study","volume":"9","author":"Anthonisen","year":"1974","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"32","key":"10.1002\/14651858.CD008870.pub2-BIB0034|cit35","first-page":"1798","article-title":"The clinical effect of salazosulphapyridine (Salazopyrin) in Crohn's disease. Report of a controlled double blind investigation","volume":"136","author":"Anthonisen","year":"1974","journal-title":"Ugeskrift for Laeger"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004836-199504000-00008","article-title":"A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission","volume":"20","author":"Arber","year":"1995","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2004.06.051","article-title":"Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease","volume":"127","author":"Ardizzone","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl A","key":"10.1002\/14651858.CD008870.pub2-BIB0038|cit38","first-page":"63A","article-title":"Mesalazine in the treatment of active Crohn's disease","volume":"2","author":"Beck","year":"1988","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD008870.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/00365521.1976.12097167","article-title":"Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease","volume":"11","author":"Bergman","year":"1976","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/00365527809179816","article-title":"Metronidazole in Crohn's disease. A double blind cross-over clinical trial","volume":"13","author":"Blichfeldt","year":"1978","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0041|cit41","first-page":"133","article-title":"Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience","volume":"14","author":"Bresci","year":"1994","journal-title":"International Journal of Clinical Pharmacology Research"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01308338","article-title":"Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease","volume":"37","author":"Brignola","year":"1992","journal-title":"Digestive Diseases and Sciences"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0016-5085(95)90059-4","article-title":"Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group","volume":"108","author":"Brignola","year":"1995","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.1994.tb00158.x","article-title":"Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)","volume":"8","author":"Caprilli","year":"1994","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2036.2003.01462.x","article-title":"Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial","volume":"17","author":"Caprilli","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1 pt 1","key":"10.1002\/14651858.CD008870.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gcb.2008.07.007","article-title":"Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"33","author":"Cezard","year":"2009","journal-title":"Gastroenterologie Clinique et Biologique"},{"issue":"Suppl G","key":"10.1002\/14651858.CD008870.pub2-BIB0047|cit47","first-page":"51","article-title":"Crohn's disease - Outcome of surgery","volume":"36","author":"Cohen","year":"2000","journal-title":"Drugs of Today"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1572-0241.1999.935_q.x","article-title":"A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"94","author":"Colombel","year":"1999","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1997.00212.x","article-title":"Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease","volume":"11","author":"Franchis","year":"1997","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"50","key":"10.1002\/14651858.CD008870.pub2-BIB0050|cit50","first-page":"1723","article-title":"[5-Aminosalicylic acid in the prevention of recurrences of Crohn's disease]","volume":"120","author":"Corso","year":"1995","journal-title":"Deutsche Medizinische Wochenschrif"},{"issue":"12","key":"10.1002\/14651858.CD008870.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/BF01536700","article-title":"Clinical relapse of Crohn's disease under standardized conservative treatment and after excisional surgery","volume":"34","author":"Dirks","year":"1989","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/978-3-642-85451-4_235","article-title":"[Prevention of recurrence by salazosulfapyridine (azulfidine) therapy in Crohn's disease. A double blind study]","volume":"82 Pt 1","author":"Ewe","year":"1976","journal-title":"Verhandlungen der Deutschen Gesellschaft fur Innere Medizin"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01823251","article-title":"Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study--initial results","volume":"364","author":"Ewe","year":"1984","journal-title":"Langenbecks Archiv f\u00fcr Chirurgie"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0054|cit54","first-page":"50","article-title":"Crohn study II: Influence of surgical radicality and salazosulfapyridine prophylaxis on postoperative relapses","volume":"64","author":"Ewe","year":"1986","journal-title":"Klinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000199850","article-title":"Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial","volume":"42","author":"Ewe","year":"1989","journal-title":"Digestion"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0056|cit56","first-page":"A11","article-title":"Prevention of Crohn's disease recurrences after intestinal resection with eudragid-l-coated 5-aminosalicylic acid. An interim report of a one year double-blind placebo controlled study (ABSTRACT)","volume":"53","author":"Fiasse","year":"1990","journal-title":"Acta Gastroenterologica Belgica"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042737-199603000-00008","article-title":"Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"8","author":"Florent","year":"1996","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2001-10708","article-title":"[Therapy of active Crohn disease with Boswellia serrata extract H 15]","volume":"39","author":"Gerhardt","year":"2001","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"9","key":"10.1002\/14651858.CD008870.pub2-BIB0060|cit60","first-page":"848","article-title":"Favorable effects of sulfasalazine on small bowel Crohn's disease: a long-term study.\"","volume":"82","author":"Goldstein","year":"1987","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0061|cit61","first-page":"186","article-title":"Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease","volume":"17","author":"Griffiths","year":"1993","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"7","key":"10.1002\/14651858.CD008870.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1023\/A:1005588911207","article-title":"Saccharomyces boulardii in maintenance treatment of Crohn's disease","volume":"45","author":"Guslandi","year":"2000","journal-title":"Digestive Diseases and Sciences"},{"issue":"9","key":"10.1002\/14651858.CD008870.pub2-BIB0063|cit63","first-page":"1343","article-title":"Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2004.06.002","article-title":"Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial","volume":"127","author":"Hanauer","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1155\/1993\/729483","article-title":"Comparative trial of remission prophylaxis in quiescent Crohn's disease with oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets","volume":"7","author":"Howaldt","year":"1993","journal-title":"Can J Gastroenterol"},{"issue":"11","key":"10.1002\/14651858.CD008870.pub2-BIB0066|cit66","first-page":"1949","article-title":"Remaining small bowel endoscopic lesions at surgery have no influence on early anastomotic recurrences in Crohn's disease","volume":"90","author":"Klein","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"26","key":"10.1002\/14651858.CD008870.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/gut.18.1.69","article-title":"Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial","volume":"18","author":"Lennard-Jones","year":"1977","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0069|cit69","first-page":"A661","article-title":"Experience with delayed-release mesalamine for maintenance of remission of Crohn's disease (CD)","volume":"136","author":"Lichtenstein","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0070|cit70","first-page":"A657","article-title":"Experience with delayed-release mesalamine for active Crohn's disease (CD)","volume":"136","author":"Lichtenstein","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0016-5085(91)90711-S","article-title":"Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV","volume":"101","author":"Lochs","year":"1991","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0016-5085(00)70208-3","article-title":"Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI","volume":"118","author":"Lochs","year":"2000","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.49.4.552","article-title":"Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study","volume":"49","author":"Mahmud","year":"2001","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00365521.1990.12067097","article-title":"Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III","volume":"25","author":"Malchow","year":"1990","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","article-title":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease","volume":"1","author":"Mantzaris","year":"2003","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD008870.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0016-5085(95)90327-5","article-title":"Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease","volume":"109","author":"McLeod","year":"1995","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S1590-8658(12)60218-7","article-title":"Early post-operative endoscopic recurrence in crohn's disease in a large prospective Italian multicenter cohort","volume":"44","author":"Orlando","year":"2012","journal-title":"Digestive and Liver Disease"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.crohns.2008.12.001","article-title":"Long-term prevention of post-operative recurrence in Crohn's disease cannot be affected by mesalazine","volume":"3","author":"Papi","year":"2009","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0016-5085(83)80017-1","article-title":"Treatment of Crohn's disease with peroral 5-aminosalicylic acid","volume":"85","author":"Rasmussen","year":"1983","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/gut.2009.194159","article-title":"Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial","volume":"59","author":"Reinisch","year":"2010","journal-title":"Gut"},{"issue":"45","key":"10.1002\/14651858.CD008870.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.3748\/wjg.v11.i45.7118","article-title":"Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study","volume":"11","author":"Romano","year":"2005","journal-title":"World Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0016-5085(82)80188-1","article-title":"A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations","volume":"83","author":"Rosen","year":"1982","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0016-5085(82)80189-3","article-title":"A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result","volume":"83","author":"Ursing","year":"1982","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0016-5085(13)60072-4","article-title":"Adalimumab Is More Effective Than Azathioprine and Mesalamine At Preventing Postoperative Recurrence of Crohn's Disease - A Randomized Trial","volume":"144","author":"Savarino","year":"2013","journal-title":"Gastroenterology"},{"issue":"45","key":"10.1002\/14651858.CD008870.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1055\/s-2008-1069077","article-title":"[Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study]","volume":"110","author":"Schneider","year":"1985","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"8","key":"10.1002\/14651858.CD008870.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.35.8.1081","article-title":"Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis","volume":"35","author":"Schreiber","year":"1994","journal-title":"Gut"},{"issue":"4 Pt2","key":"10.1002\/14651858.CD008870.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0016-5085(79)90388-3","article-title":"A trial of sulfasalazine as adjunctive therapy in Crohn's disease","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD008870.pub2-BIB0091|cit91","first-page":"721","article-title":"[Basic diet in Crohn's disease]","volume":"131","author":"Stober","year":"1983","journal-title":"Monatsschr Kinderheilkd"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0016-5085(97)70117-3","article-title":"A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group","volume":"112","author":"Sutherland","year":"1997","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0093|cit93","first-page":"491","article-title":"Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease","volume":"12","author":"Tao","year":"2009","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0094|cit94","first-page":"12","article-title":"Enteral nutrition in the short-term treatment of active inflammatory bowel diseases: A single-centre experience","volume":"19","author":"Terranova","year":"2001","journal-title":"Rivista Italiana di Nutrizione Parenterale ed Enterale"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0095|cit95","first-page":"401","article-title":"A semielemental diet (Pregomin) as primary therapy for inducing remission in children with active Crohn's disease","volume":"25","author":"Terrin","year":"2002","journal-title":"Italian Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.1995.tb00438.x","article-title":"Mesalazine (Mesasal\/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease","volume":"9","author":"Thomson","year":"1995","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0097|cit97","first-page":"113","article-title":"Maintenance treatment of Crohn's disease with a polymeric feed rich in TGF-beta","volume":"23","author":"Triantafillidis","year":"2010","journal-title":"Annals of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD008870.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gut.27.7.814","article-title":"Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid","volume":"27","author":"Wellmann","year":"1986","journal-title":"Gut"},{"issue":"Supplement A","key":"10.1002\/14651858.CD008870.pub2-BIB0099|cit99","first-page":"71A","article-title":"New oral preparations for maintenance therapy in Crohn's disease (abstract)","volume":"2","author":"Wellmann","year":"1988","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/00365527809181743","article-title":"The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial","volume":"13","author":"Wenckert","year":"1978","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"10.1002\/14651858.CD008870.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/ibd.20915","article-title":"Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study","volume":"15","author":"Yamamoto","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"8044","key":"10.1002\/14651858.CD008870.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0016-5085(82)80190-X","article-title":"Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978","volume":"83","author":"Binder","year":"1982","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1002\/14651858.CD008870.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/(SICI)1097-0258(19991015)18:19<2593::AID-SIM392>3.0.CO;2-T","article-title":"Examining the minimum important difference","volume":"18","author":"Brant","year":"1999","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","article-title":"Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives","volume":"35","author":"Cellier","year":"1994","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/gut.15.6.435","article-title":"Short-term course and prognosis of Crohn's disease","volume":"15","author":"Dombal","year":"1974","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"9","key":"10.1002\/14651858.CD008870.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/gut.2006.093484","article-title":"PPARgamma as a new therapeutic target in inflammatory bowel diseases","volume":"55","author":"Dubuquoy","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1542-3565(04)00121-1","article-title":"5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion","volume":"2","author":"Feagan","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD008870.pub2-BIB0112|cit112","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"7650","key":"10.1002\/14651858.CD008870.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0115|cit115","first-page":"81","article-title":"The state of the art in the management of inflammatory bowel disease","volume":"3","author":"Hanauer","year":"2003","journal-title":"Reviews in Gastroenterological Disorders"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0117|cit117","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ibd.21813","article-title":"Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease","volume":"18","author":"Levesque","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD008870.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1111\/j.1572-0241.2000.03342.x","article-title":"Progress in understanding the mechanisms of action of 5-aminosalicylic acid","volume":"95","author":"MacDermott","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008870.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.psychres.2004.06.011","article-title":"Assessing publication bias in genetic association studies: evidence from a recent meta-analysis","volume":"129","author":"Munafo","year":"2004","journal-title":"Psychiatry Research"},{"issue":"11","key":"10.1002\/14651858.CD008870.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/gut.28.11.1474","article-title":"Influence of olsalazine on gastrointestinal transit in ulcerative colitis","volume":"28","author":"Rao","year":"1987","journal-title":"Gut"},{"issue":"8","key":"10.1002\/14651858.CD008870.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma","volume":"201","author":"Rousseaux","year":"2005","journal-title":"Journal of Experimental Medicine"},{"issue":"13","key":"10.1002\/14651858.CD008870.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008870.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/j.1572-0241.2002.07092.x","article-title":"Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis","volume":"97","author":"Sandborn","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2036.2003.01661.x","article-title":"Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm","volume":"18","author":"Sandborn","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD008870.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2003.035253","article-title":"CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial","volume":"53","author":"Sandborn","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008870.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008870.pub2-BIB0130|cit130","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD008870.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2004.01.024","article-title":"A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease","volume":"126","author":"Su","year":"2004","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1002\/14651858.CD008870.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJM200111293452221","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. Correction","volume":"345","author":"Thomsen","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008870.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/00365528309182095","article-title":"Serum antibodies to Bacteroides species in chronic inflammatory bowel disease","volume":"18","author":"Tvede","year":"1983","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008870.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00003495-199141040-00009","article-title":"Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease","volume":"41","author":"Wadworth","year":"1991","journal-title":"Drugs"},{"issue":"12","key":"10.1002\/14651858.CD008870.pub2-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","author":"Lim","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008870.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:58:19Z","timestamp":1718611099000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008870.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,3]]},"references-count":135,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008870.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,3]]}}}